Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH‐SY5Y neuroblastoma cells
- 1 June 2010
- journal article
- research article
- Published by Wiley in Journal of Pineal Research
- Vol. 49 (2) , 141-148
Abstract
Abstract: Melatonin is a potent free radical scavenger, antioxidant and neuroprotective drug. On the other hand, galantamine is a cholinergic drug with antioxidant and neuroprotective properties linked to inhibition of acetylcholinesterase and allosteric modulation of nicotinic receptors. This investigation evaluated a possible synergistic neuroprotective effect of subeffective concentrations of combined galantamine and melatonin. Human neuroblastoma SH‐SY5Y cells were subjected to a mitochondrial oxidative stress, by blockade of mitochondrial complexes I and V with rotenone and oligomycin‐A (R/O); cells were treated for 24 hr with R/O. This caused 40% of the cell to die as measured by lactate dehydrogenase (LDH) release. Cell incubation with increasing concentrations of galantamine (10–300 n m ) or melatonin (0.3–10 n m ) for 24 hr, followed by a 24‐hr period with R/O, caused a concentration‐dependent protection; maximum protection was achieved with 300 n m galantamine (56% protection) and 10 n m melatonin (50% protection). Combination of subeffective concentrations of melatonin (0.3 n m ) and galantamine (30 n m ) caused a synergistic and significant protection that was similar to the maximum protection afforded by effective concentrations of melatonin or galantamine alone. This protective effect was completely reversed when nicotinic and melatonin receptors were blocked respectively by mecamylamine and luzindole. The neuroprotective effect was prevented by chelerythrine, LY294002, and Sn (IV) protoporphyrin IX dichloride (SnPP), indicating the participation of the PKC/PI3K/Akt activation and induction of the antioxidant enzyme heme oxygenase‐1. The synthesis of novel multitarget compounds having in a single molecule the combined neuroprotective properties of galantamine and melatonin could be a new strategy for potential therapeutic agents in neurodegenerative diseases.Keywords
This publication has 51 references indexed in Scilit:
- Inflammatory Mediators Leading to Protein Misfolding and Uncompetitive/Fast Off‐Rate Drug Therapy for Neurodegenerative Disorders2007
- Oxidative stress in Alzheimer's diseasePathophysiology, 2006
- Indicators of neuroprotection with galantamineBrain Research Bulletin, 2005
- Oxidative stress mechanisms and potential therapeutics in Alzheimer diseaseJournal of Neural Transmission, 2004
- Oxidative stress, cell cycle, and neurodegenerationJournal of Clinical Investigation, 2003
- Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death1Neurobiology of Aging, 2002
- Protein modification by the lipid peroxidation product 4‐hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patientsAnnals of Neurology, 1998
- Electrochemical Analysis of Protein Nitrotyrosine and Dityrosine in the Alzheimer Brain Indicates Region-Specific AccumulationJournal of Neuroscience, 1998
- Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivoLife Sciences, 1990
- Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's DiseaseJournal of Neurochemistry, 1989